CLAIMS

What is claimed is:

1. Use of a pharmaceutical composition in the manufacture of a medicament for preventing or delaying the onset of hepatocellular cancer, wherein the pharmaceutical composition comprises a combination of short chain fatty acids, wherein the combination consists of acetic acid or a pharmaceutically acceptable salt thereof, propionic acid or a pharmaceutically acceptable salt thereof, and butyric acid or a pharmaceutically acceptable salt thereof.

2. The use according to claim 1, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

3. The use according to claim 1 or 2, wherein the pharmaceutical composition is for administration in combination with another therapeutic agent.

4. The use according to claim 1-3, wherein the pharmaceutical composition is for oral administration.

5. The use according to claim 4, wherein the pharmaceutical composition is for administration with food or drink.

6. Use of a pharmaceutical composition in the manufacture of a medicament for treating liver disease in a subject, wherein the pharmaceutical composition comprises a combination of short chain fatty acids, wherein the combination consists of acetic acid or a pharmaceutically acceptable salt thereof, propionic acid or a pharmaceutically acceptable salt thereof, and butyric acid or a pharmaceutically acceptable salt thereof.

7. The use according to claim 6, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

8. The use according to claim 6 or 7, wherein the pharmaceutical composition is for administration in combination with another therapeutic agent.

9. The use according to any one of claims 6-8, wherein the pharmaceutical composition is for oral administration.

10. The use according to claim 9, wherein the pharmaceutical composition is for administration with food or drink.

11. The use according to any one of claims 6-10, wherein the liver disease is liver cancer.

12. Use of a combination of short chain fatty acids in the manufacture of a kit for preventing or delaying the onset of hepatocellular cancer, wherein the combination consists of acetic acid or a pharmaceutically acceptable salt thereof, propionic acid or a pharmaceutically acceptable salt thereof, and butyric acid or a pharmaceutically acceptable salt thereof.

13. Use of a combination of short chain fatty acids in the manufacture of a kit for preventing or delaying the onset of liver disease, wherein the combination consists of acetic acid or a pharmaceutically acceptable salt thereof, propionic acid or a pharmaceutically acceptable salt thereof, and butyric acid or a pharmaceutically acceptable salt thereof.

14. The claim 13, wherein the liver disease is liver cancer.